Dave Rosenberg has left a managing director position at GE Ventures to head Merck Group unit M Ventures' New Business Fund.

OSF Ventures and Wanxiang Healthcare Investments are among the backers of a $45m series D round in heart monitoring platform Endotronix.

Biocon, which owns nearly a fifth in the company thanks to a licensing agreement, is in line for an exit when Equillium lists on the Nasdaq Global Market.

Corporate venturing unit Trumpf Venture invested $4.5m to help the diabetes monitor developer close the round at $12.1m.

RSP Systems, a spinout of University of Southern Denmark, has extended its series B round to $12.1m following a $4.5m extension backed by Trumpf Venture.

The immuno-oncology therapy developer's investors include Pfizer and Gilead Sciences, both of which contributed to a $300m round in January.

The psychiatric and neurological disease drug developer has secured $25m in a series B round co-led by Pfizer Ventures.

The GSK-backed small molecule drug developer floated at the top of its range to raise just over $106m.

Cancer drug developer ViraTherapeutics has been acquired by Boehringer Ingelheim, three years after the corporate led its series A round.

Oncology diagnostics technology developer Epic Sciences, whose investors include Genomic Health, Pfizer and Roche, has now raised at least $135m in total.